Generic,Specialised,Abbreviations
Adenocarcinoma,fluorouracil,ARCC
anal cancer,nivolumab,IMW
anal carcinoma,pembrolizumab,AACR
androgen deprivation therapy,tumor markers,AACRIO25
auger electron therapy,biomarkers,ACCC
basal cell carcinoma,circulating tumor cells,ADC
bile duct cancer,minimal residual disease,ADCC
biliary tract cancer,5-fluorouracil,ADCs
bladder cancer,abiraterone,ADORE
bladder cancer,abiraterone acetate,AK112
bone cancer,abiraterone and prednisolone,ALK
bone metastases,abemaciclib,ALL
bone scan,acalabrutinib,AML
brain cancer,acquired resistance mechanisms,ASCO
brain tumor,adenocarcinoma at ge junction,ASCO20
breast cancer,adoptive cell transfer,ASCO21
Breast cancer,afatinib,ASCO22
breast cancer,aldoxorubicin,ASCO23
breast cancer treatment,alectinib,ASCO25
breast cancers,alkeran,ASCT
bridge therapy,alkylating agents,ASTRO
cancer,allogeneic car-t,AUA
cancer doctor,alpha particle therapy,AXL
cancer fatigue,alpelisib,BC
cancer immunology,american association for cancer research,BCL-2
cancer metabolism,american cancer society,BCL 2
cancer prevention,american society of clinical oncology,BCL-XL
cancer screening,amivantamab,BCL XL
cancer stem cells,anaplastic astrocytoma,BCMA
carcinoid tumor,anaplastic lymphoma kinase,BCR-ABL
carcinoma,anastrozole,BET
cervical cancer,androgen receptor,BH3
chemotherapy,aneuploidy,BRAF
chronic lymphocytic leukemia,angiogenesis,BRCA1
chronic lymphoid leukemia,angiogenesis inhibitors,BRCA2
chronic myeloid leukemia,angiosarcoma,BTK
chronic myelomonocytic leukemia,anti-apoptotic proteins,BiTE
colorectal cancer,antibody drug conjugates adcs,CAR T
colorectal cancer,antimetabolites,CAR
Colorectal Cancer,apoptosis,CAR-M
colo-rectal cancer,armored car-t,CAR-NK
damp release,astrocytoma,CAR-T
deep learning pathology,atezolizumab,CAR-Treg
diffuse type gastric cancer,auristatin derivatives,CB/CC
diffuse-type gastric cancer,aurora kinase inhibitor,CC-92480
digital biomarkers,avelumab,CCR4
Esophageal Cancer,axitinib,CD123
eye cancer,axl receptor,CD19
fallopian tube cancer,base editing car-t,CD20
fluorescence guided surgery,bcell lymphoma 2,CD22
follicular lymphoma,bcr-abl,CD25
gall bladder cancer,belzutifan,CD26
gastric cancer,bendamustine,CD30
Gastric Cancer,beta particle therapy,CD33
Gastric Cancers,bevacizumab,CD38
Gastric/GEJ Cancers,bh3 mimetics,CD47
Gastroesophageal Cancer,bintrafusp alfa,CD70
gastroesophageal junction cancer,bispecific antibodies,CD8
gastrointestinal stromal tumor,bispecific t cell engagers,CDC
gene therapy,blinatumab,CDK
Genitourinary Cancer,bortezomib,CDK4
genomic testing,braftovi,CDK4/6
germ cell tumor,brca1,CDK6
gynecologic oncology,brca2,CELMoD
gynecologic oncology,brachytherapy,CELMoDs
hairy cell leukemia,brigatinib,CHC
head and neck squamous cell carcinoma,bromodomain inhibitors,CHRYSALIS-2
hematology oncology,bypass pathways,CHRYSALIS2
hepatocellular carcinoma,bystander effect,CHRYSALIS 2
hypofractionated radiotherapy,cabazitaxel,CLDN18.2
inflammatory breast cancer,cabozantinib,CLL
interferon,cadonilimab,CML
intrathecal therapy,calicheamicin,CN201
intrinsic resistance,calquence,CNS
invasive ductal carcinoma,calreticulin exposure,COMy
invasive lobular carcinoma,cancer associated anemia,CR
kidney cancer,cancer cachexia,CRC
Kidney Cancer,cancer fatigue,CRPC
kidney cancer,cancer immunology,CRS
kidney cancer,cancer metabolism,CS1
liquid biopsy,cancer stem cells,CSCs
liquid biopsy,capecitabine,CTCs
liver cancer,car-nk cells,CTLA-4
lower esophageal carcinoma,car-m cells,CTX-009
lung cancer,car-t cell therapy,CXCR4
lung cancer,car-t manufacturing,ColoAd1
male breast cancer,carboplatin,DAMP
metastasis,carcinogenesis,DFCI
metastatic,carcinoid syndrome,DIPG
minimally invasive surgery,carcinomatosis,DNA
mr-guided radiotherapy,cardio-oncology,DNMT
Multiple Myeloma,catumaxomab,DS-1062
Myeloma,ceritinib,DS-6000
neoadjuvant therapy,cereblon modulator,DS6000
neoplasm,cetuximab,DX
neuroendocrine tumor,checkpoint inhibitor,DXd
nodular lymphoma,chemotherapy induced neuropathy,Dato-DXd
Oncology,cholangiocarcinoma,E3
oral cancer,chordoma,EBMT
ovarian cancer,chromatin remodeling,ECO
pancreatic and peritoneal cancer,chromothripsis,ECOG
pancreatic cancer,chromosomal instability,EGF
pancreatic cancers,cisplatin,EGFR
papillary thyroid cancer,cleavable linkers,EHA
pediatric oncology,clinical decision support,ELCC
pituitary tumor,cloud-based platforms,EMT
pleural mesothelioma,claudin 18.2,EONS
precision dosing,conditionally active car-t,ERBB2
precision medicine,conditional immune cell engagers,ESCC
precision oncology,crizotinib,ESGO
precision oncology,crossover resistance,ESMO
primary central nervous system lymphoma,cytokine release syndrome,ESMO21
primary peritoneal cancer,cyclophosphamide,ESO
prostate cancer,cytoxan,EZH2
proton therapy,dabrafenib,EnAd
pulmonary neuroendocrine tumor,darovasertib,FAM
radiation oncology,datopotamab deruxtecan,FCRH5
radiopharmaceuticals,datroway,FDA
radiotherapy,placebo plus chemotherapy,FLT-3
rare cancer,pembrolizumab plus chemotherapy,FLT3
real-time tissue analysis,divarasib,FMS
rectal cancer,dnmt inhibitors,FOWARC
Relapsed Myeloma,docetaxel,FRA
renal cell carcinoma,dordaviprone,G12C
resistance,doxorubicin,G12D
robotic surgery oncology,ductal carcinoma in situ,G13C
salvage therapy,dual car-t,GAS6
sarcoma,dual targeting antibodies,GCPT
second-line therapy,duocarmycin,GCT
selective internal radiation,durvalumab,GE
sequential therapy,dxd payload,GEJ
signet ring cell carcinoma,e3 ligase modulator,GI
single cell sequencing,efflux pumps,GIST
single port surgery,elotuzumab,GPRC5D
skin cancer,emrelis,GU
small lymphocytic lymphoma,enhertu,GVT
soft tissue sarcoma,enzymatically cleavable,H3K27
solid tumor,enzalutamide,H3K27M
splenic lymphoma,ependymoma,H3K4
squamous cell carcinoma,epcoritamab,HER-2
stem cell transplant,epigenetic therapy,HER2
stereotactic radiation,epigenetics,HER2-CLIMB
surgical oncology,erlotinib,HER2CLIMB
targeted therapy,estrogen receptor,HLH
telemedicine oncology,etoposide,HMAs
testicular cancer,european society for medical oncology,HRD
thyroid cancer,everolimus,HSPC
tumor,fam-trastuzumab deruxtecan,IBC
urothelial cancer,fam-trastuzumab deruxtecan t-dxd,ICANS
urothelial carcinoma,fatty acid synthesis,ICFBC
vaginal cancer,fcrh5,ICOS
viral immunotherapy,ferroptosis,IGF-1R
vulvar cancer,fibrosarcoma,IL3RA
,flt3 inhibitor,IME
,dabrafenib mesylate,FGF
,renal cell carcinoma,FGFR
,daratumumab,FISH
,entrectinib,HDAC
,flotetuzumab,IMS
,fluorouracil combinations,IMiDs
,folate receptor alpha,IPI-549
,fragmentomics,JAK
,fulvestrant,JAK-STAT
,gamma delta car-t,JAK2
,gamma knife,JNJ-61186372
,gas6 protein s,KCA
,gefitinib,KIF18A
,gemcitabine,KN046
,genomic instability,KRAS
,glioblastoma,LAG-3
,glioblastoma multiforme,LIBRETTO-431
,glofitamab,LIBRETTO431
,glucose transporter 1,M2
,glutaminase inhibitors,MAPK
,glutathione sensitive,MARIPOSA
,glycolysis inhibitors,MARIPOSA-2
,gprc5d,MARIPOSA2
,h3k27 methylation,MAS
,h3k4 methylation,MASCC
,hairy cell leukemia variant,MCED
,hepatoma,MCL
,hereditary cancer syndrome,MCL1
,hexokinase,MDM2
,histone deacetylase inhibitors,MDS
,histone modifications,MDSCs
,homologous recombination deficiency,MEK
,hormone receptor positive,MER
,hyperthermia,MET
,hypomethylating agents,MGD009
,ibtrozi,MGD013
,ibritumomab,MM
,icos agonists,MMPs
,idelalisib,MMR
,imatinib,MOASC
,ime degraders,MRD
,immune effector cell associated neurotoxicity syndrome,MSI
,immune infiltration score,MTD
,immune priming,NAM
,immune stimulating payloads,NCCN
,immunogenic cell death,NSCLC
,immunohistochemistry,ONS
,immunooncology,OSU
,immunosuppressive microenvironment,OSUCCC
,immunosuppressive tumor microenvironment,OX40
,imbruvica,PAPILLON
,induced pluripotent stem cell car-t,PARP
,inlyta,PBDs
,ipi-549,PC
,ipilimumab,PD
,irinotecan,PD-1
,ivonescimab,PD-L1
,jakafi,PDL1
,jnj-61186372,PET
,kalydeco,PETACC-6
,keytruda,PETACC6
,kif18a,PI3K
,kn046,PIK3CA
,lactate dehydrogenase,PROTAC
,lag-3,PSA
,lapatinib,PSMA
,larotrectinib,RAD-1901
,laundic acid,RAD1901
,lenalidomide,RCC
,lenvatinib,RET
,letrozole,RIC
,letrozole for ovulation induction,RLT
,leukemia stem cells,RNA
,linvoseltamab,ROR1
,linvoseltamab gcpt,ROR2
,liposarcoma,ROS1
,lobular carcinoma in situ,RRMM
,logic gated car-t,SABCS
,lorlatinib,SBRT
,lumakras,SCLC
,luminal a,SERD
,luminal b,SHR-1701
,lutetium-177,SIOG
,lymphatic mapping,SIRPA
,lynozyfic,SLAM7
,lynparza,SOBO
,mammography,SOS
,marginal zone lymphoma mzl,SWOG
,maytansine derivatives,T-DXd
,mcl1 inhibitor,TAMs
,mced tests,TCR
,mdm2 ligase,TCR-T
,medulloepithelioma,TCR T
,melanoma vaccine,TIGIT
,mer receptor,TIL
,metabolic reprogramming,TILs
,metabolomics,TIM-3
,metastatic escc,TKIs
,mgd009,TLS
,mgd013,TMB
,microsatellite instability,TNBC
,microsatellite stable,TNM
,minimal residual disease,TP53
,mitochondrial metabolism,TRAC
,mitomycin,TRK
,mitomycin sustained release,TROP-2
,mitoxantrone,TROP2
,model informed drug development,TYRO3
,molecular glues,VEGF
,molecular imaging surgery,VEGFR
,molecular profiling,VEGFR-2
,molecular subtype,VHL
,mosunetuzumab,VISTA
,mrna cancer vaccines,VLS-1488
,multi-cancer early detection,VOD
,multi-drug resistance,ctDNA
,multiple myeloma oncogene 1,mCRC
,multispecific antibodies,mCRPC
,mutational burden,mHSPC
,myelodysplastic neoplasms,mTOR
,myelodysplastic syndrome,ABVD
,myelofibrosis,ABVE
,myeloid derived suppressor cells mdscs,ABVE-PC
,national cancer institute,BEACOPP
,national comprehensive cancer network,BEP
,nectin-4,CAF
,necroptosis,CAPOX
,neoantigen load,CEM
,neoantigen vaccines,CEV
,neratinib,CMF
,neuroblastoma,COPDAC
,neurofibromatosis,COPP
,next generation adcs,COPP-ABV
,next generation car-t,CVP
,niraparib,FEC
,niraparib and abiraterone,FOLFIRINOX
,nivolumab,FOLFOX
,nivolumab and ipilimumab,FU-LV
,nivolumab and relatlimab,JEB
,non-cleavable linkers,MOPP
,off-the-shelf car-t,MVAC
,odronextamab,OEPA
,olaparib,OPPA
,oligodendroglioma,PCV
,oncolytic virus,PEB
,oncolytic viruses,R-CHOP
,oncotype dx,R-CVP
,opdivo,R-EPOCH
,orphan drug,XELIRI
,osimertinib,XELOX
,osteosarcoma,GEP-NET
,ox40 agonists,mCRC
,oxidative phosphorylation,CRC
,oxaliplatin,MSI-H
,paclitaxel,dMMR CRC
,paclitaxel and encequidar,RCC
,paclitaxel poliglumex,aRCC
,palbociclib,ccRCC
,panitumumab,mRCC
,paraganglioma,nccRCC
,pazopanib,XB628
,pbds,XB010
,pembrolizumab,ADU-1805
,pemigatinib,XL309
,peptide vaccines,
,personalized cancer vaccines,
,pertuzumab,
,pertuzumab and trastuzumab,
,pharmacokinetic modeling,
,pheochromocytoma,
,philadelphia chromosome,
,pituitary adenoma,
,pivekimab sunirine,
,platelet-derived growth factor receptor,
,point-of-care car-t,
,pomalidomide,
,population pharmacokinetics,
,pro-apoptotic proteins,
,probody car-t,
,prognosis prediction,
,progesterone receptor,
,prostate specific antigen,
,proteasome inhibitor,
,protein degradation therapy,
,proteolysis targeting chimera,
,proteolytically cleavable,
,proteomics profiling,
,pyroptosis,
,pyrrolobenzodiazepine pbds,
,pyruvate kinase m2,
,quantitative systems pharmacology,
,radio-darpin,
,radioemibolization,
,radiogenomics,
,refractory,
,regulatory t cells tregs,
,resistance mutations,
,rhabdomyosarcoma,
,rituximab,
,ror1,
,ror2,
,rucaparib,
,sacituzumab govitecan,
,sbrt,
,sentinel lymph node,
,shr-1701,
,siglec-15,
,sir-spheres,
,site specific conjugation,
,slam7,
,sorafenib,
,sotorasib,
,spatial transcriptomics,
,stem cell transplantation,
,subcutaneous nivolumab,
,subclonal diversity,
,sunitinib,
,sunvozertinib,
,survival analysis,
,switch car-t,
,synergistic combinations,
,synthetic biology car-t,
,t cell dysfunction,
,t cell redirecting antibodies,
,t-dxd,
,talazoparib,
,taletrectinib,
,talimogene laherparepvec,
,talquetamab,
,tamoxifen,
,tancar,
,targeted protein degradation,
,taxane,
,tecentriq,
,teclistamab,
,telisotuzumab vedotin,
,temozolomide,
,ternary complex formation,
,thalidomide,
,therapeutic radioisotope,
,tigit checkpoint,
,tim-3 checkpoint,
,tissue factor,
,tislelizumab,
,tislelizumab+chemotherapy,
,topoisomerase inhibitor,
,topoisomerase inhibitors,
,topotecan,
,trac deletion,
,trastuzumab,
,trastuzumab deruxtecan,
,trastuzumab duocarmazine,
,trastuzumab emtansine,
,treatment recommendation,
,treatment response prediction,
,trop2,
,tucatinib,
,tumor associated macrophages,
,tumor associated macrophages tams,
,tumor evolution,
,tumor heterogeneity,
,tumor infiltrating lymphocytes,
,tumor microenvironment,
,tumor mutational burden,
,tumor mutational signature,
,tumor necrosis factor alphainduced protein 3,
,tumor suppressor gene,
,tyro3,
,tyrosine kinase inhibitor,
,ultra-hypofractionation,
,undruggable targets,
,universal car-t,
,vascular endothelial growth factor,
,vemurafenib,
,venclexta,
,venetoclax,
,venetoclax resistance,
,vepdegestrant,
,vhl ligase,
,vinblastine,
,vincristine,
,vinorelbine,
,virtual tumor boards,
,vista,
,vista checkpoint,
,vls-1488,
,votrient,
,waldenstrom macroglobulinemia,
,warburg effect,
,welireg,
,whole exome sequencing,
,whole genome sequencing,
,xeloda,
,yervoy,
,yttrium-90,
,zaltrap,
,zegfrovy,
,zelboraf,
,zongertinib,
,zusduri,
,zydelig,
,zytiga,
,European Lung Cancer Congress 2025,
,San Antonio Breast Cancer Symposium,
,The American Society for Radiation Oncology,
,The European Cancer Organisation,
,The European Society for gynaecological oncology,
,The European Oncology Nursing society,
,The European School of Oncology,
,The International Society of Geriatric Oncology,
,The multinational Association of Supportive care in cancer,
,solid tumors,
,enadenotucirev,
,atezolizumab,
,gilteritinib,
,tazemetostat,
,International Congress on the Future of Breast Cancer,
,School of Breast Oncology,
,Canadian Hematology Conference,
,Dana-Farber Cancer Institute,
,Cereblon E3 Ligase Modulators,
,Mezigdomide,
,European Society for Blood and Marrow Transplantation,
,International Myeloma Society,
,Dana Farber Cancer Institute,
,World Congress on Controversies in Multiple Myeloma,
,International Myeloma Workshop,
,Ramucirumab,
,National Academy of Medicine,
,Immunotherapy Patient Summit,
,Ohio State University Comprehensive Cancer Center,
,Kidney Cancer Association,
,Medical Oncology Association of Southern California,
,American Society of Clinical Oncology,
,Genitourinary Cancers,
,peritoneal cancers,
,American Urological Association,
,genitourinary cancers,
,Tivozanib,
,Sorafenib,
,Elacestrant,
,Sacituzumab govitecan,
,Trodelvy,
,Mastectomy,
,Immunotherapeutic,
,urologic cancers,
,oncogenic,
,all-trans retinoic acid,
,bcl-2 family,
,bcl-2 inhibitor,
,bcl-xl inhibitor,
,bet inhibitors,
,braf inhibitor,
,braf mutation,
,bulk rna sequencing,
,car-treg cells,
,car-treg therapy,
,chronic lymphocytic leukemia cll,
,circulating tumor dna,
,dipg treatment,
,dna damage response,
,dna methylation,
,dna methyltransferase inhibitors,
,egfr inhibitor,
,egfr mutation,
,egfr tyrosine kinase inhibitor,
,egfr x met bispecific,
,hdac inhibitors,
,her2 negative,
,her2 positive,
,her2-targeted therapy,
,igf-1r,
,jak inhibitor,
,kras g12c,
,kras g12c inhibitors,
,kras g12d inhibitors,
,kras g13c inhibitors,
,kras inhibitor,
,mantle cell lymphoma mcl,
,metastatic nsclc,
,protac,
,ros1,
,secondary aml,
,therapy related aml,
,til therapy,
,tumor infiltrating lymphocytes til therapy,
,vegf inhibitor,
,The SWOG cancer research network,
,Annual ONS Congress,
,acute myeloid leukemia,
,acute megakaryoblastic leukemia,
,acute promyelocytic leukemia,
,adaptive radiotherapy,
,adenocarcinoma,
,adenoid cystic carcinoma,
,adrenal cancer,
,adrenocortical carcinoma,
,ampullary adenocarcinoma,
,anaplastic thyroid cancer,
,atypical chronic myeloid leukemia,
,b cell prolymphocytic leukemia,
,b-cell lymphoma,
,car-m therapy,
,car-nk therapy,
,metastatic castration-resistant prostate cancer,
,metastatic hormone-sensitive prostate cancer,
,tislelizumab plus chemotherapy,
,tislelizumab v/s chemotherapy,
,tislelizumab versus chemotherapy,
,triple negative breast cancer,
,upper esophageal carcinoma,
,leukaemic nonnodal mantle cell lymphoma,
,synovial sarcoma,
,t-cell lymphoma,
,tcell prolymphocytic leukemia,
,tcr-t therapy,
,acute lymphoblastic leukemia,
,burkitt lymphoma,
,desmoplastic small round cell tumor,
,esophageal squamous cell carcinoma,
,extranodal marginal zone lymphoma,
,marginal zone bcell lymphoma,
,metastatic castration resistant prostate cancer,
,metastatic esophageal squamous cell carcinoma,
,pancreatic ductal adenocarcinoma,
,pancreatic neuroendocrine tumor,
,anti-angiogenic therapy,
,bone marrow biopsy,
,bone marrow transplant,
,castration resistant prostate cancer,
,diffuse large b cell lymphoma,
,epithelial ovarian cancer,
,esophageal adenocarcinoma,
,esophageal cancer,
,ewing sarcoma,
,extensive-stage small cell lung cancer,
,follicular large cell lymphoma,
,glioblastoma immunotherapy,
,glioma,
,h3k27m mutant glioma,
,hodgkin lymphoma,
,hurthle cell cancer,
,indolent lymphoma,
,kaposi sarcoma,
,leukemia,
,limited-stage small cell lung cancer,
,lung adenocarcinoma,
,lung squamous cell carcinoma,
,lymphoblastic lymphoma,
,lymphoma,
,lymphoplasmacytic lymphoma,
,malignant glioma,
,malignant melanoma,
,malignant mesothelioma,
,malt lymphoma,
,mantle cell lymphoma,
,marginal zone lymphoma,
,medullary thyroid cancer,
,melanoma,
,merkel cell carcinoma,
,mesothelioma,
,metastatic breast cancer,
,metastatic colorectal cancer,
,metastatic melanoma,
,metastatic pancreatic cancer,
,metastatic prostate cancer,
,middle esophageal carcinoma,
,multiple myeloma,
,myeloid sarcoma,
,myeloproliferative neoplasm,
,nasopharyngeal carcinoma,
,non-hodgkin lymphoma,
,non-small cell lung cancer,
,pancreatic adenocarcinoma,
,brain metastases,
,wilms tumor,
,small cell lung cancer,
,5-FU,
,Abecma,
,Abemaciclib,
,Abiraterone Acetate,
,Abraxane,
,Acalabrutinib Maleate Monohydrate,
,Acalabrutinib Maleate Monohydrate,
,Actemra,
,Adagrasib,
,Adcetris,
,Ado-Trastuzumab Emtansine,
,Adriamycin,
,Adstiladrin,
,Afamitresgene Autoleucel,
,Afatinib Dimaleate,
,Afinitor,
,Akeega,
,Akynzeo,
,Aldara,
,Aldesleukin,
,Alecensa,
,Alectinib,
,Alemtuzumab,
,Alimta,
,Alkeran for Injection,
,Alkeran Tablets,
,Aloxi,
,Alpelisib,
,Alunbrig,
,Alymsys,
,Ameluz,
,Amifostine,
,Aminolevulinic Acid Hydrochloride,
,Amivantamab-vmjw,
,Amtagvi,
,Anastrozole,
,Anktiva,
,Apalutamide,
,Aprepitant,
,Aranesp,
,Aredia,
,Arimidex,
,Aromasin,
,Arranon,
,Arsenic Trioxide,
,Arzerra,
,Asciminib Hydrochloride,
,Asciminib Hydrochloride,
,Asparaginase Erwinia Chrysanthemi,
,Asparaginase Erwinia Chrysanthemi [Recombinant]-rywn,
,Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn,
,Asparlas,
,Atezolizumab,
,Atezolizumab and Hyaluronidase-tqjs,
,Aucatzyl,
,Augtyro,
,Avapritinib,
,Avastin,
,Avelumab,
,Axicabtagene Ciloleucel,
,Axitinib,
,Ayvakit,
,Azacitidine,
,Azedra,
,Balversa,
,Bavencio,
,Beleodaq,
,Belinostat,
,Belzutifan,
,Bendamustine Hydrochloride,
,Bendeka,
,Besponsa,
,Besremi,
,Bevacizumab,
,Bevcizumab,
,Bexarotene,
,Bicalutamide,
,BiCNU,
,Binimetinib,
,Bizengri,
,Bleomycin Sulfate,
,Blinatumomab,
,Blincyto,
,Bortezomib,
,Bosulif,
,Bosutinib,
,Braftovi,
,Brentuximab Vedotin,
,Brexucabtagene Autoleucel,
,Breyanzi,
,Brigatinib,
,Brukinsa,
,BuMel,
,Busulfan,
,Busulfex,
,Cabazitaxel,
,Cablivi,
,Cabometyx,
,Cabozantinib-S-Malate,
,Calaspargase Pegol-mknl,
,Calquence,
,Camcevi,
,Campath,
,Camptosar,
,Capecitabine,
,Capivasertib,
,Caplacizumab-yhdp,
,Capmatinib Hydrochloride,
,Capmatinib Hydrochloride,
,Carac,
,Carboplatin,
,Carfilzomib,
,Carmustine,
,Carmustine Implant,
,Carvykti,
,Casodex,
,Cemiplimab-rwlc,
,Ceritinib,
,Cervarix,
,Cetuximab,
,Chlorambucil,
,Ciltacabtagene Autoleucel,
,Cisplatin,
,Cladribine,
,Clofarabine,
,Clolar,
,Cobimetinib Fumarate,
,Cobimetinib Fumarate,
,Columvi,
,Cometriq,
,Copiktra,
,Cosibelimab-ipdl,
,Cosmegen,
,Cotellic,
,Crizotinib,
,Cyclophosphamide,
,Cyramza,
,Cytarabine,
,Dabrafenib Mesylate,
,Dacarbazine,
,Dacogen,
,Dacomitinib,
,Dactinomycin,
,Danyelza,
,Daratumumab,
,Daratumumab and Hyaluronidase-fihj,
,Darbepoetin Alfa,
,Darolutamide,
,Darzalex,
,Darzalex Faspro,
,Dasatinib,
,Datopotamab Deruxtecan-dlnk,
,Datroway,
,Daunorubicin Hydrochloride,
,Daunorubicin Hydrochloride and Cytarabine Liposome,
,Daurismo,
,Decitabine,
,Decitabine and Cedazuridine,
,Defibrotide Sodium,
,Defitelio,
,Degarelix,
,Denileukin Diftitox-cxdl,
,Denosumab,
,Dexamethasone,
,Dexrazoxane Hydrochloride,
,Dinutuximab,
,Docetaxel,
,Dostarlimab-gxly,
,Doxil,
,Doxorubicin Hydrochloride,
,Doxorubicin Hydrochloride Liposome,
,Durvalumab,
,Duvelisib,
,Eflornithine Hydrochloride,
,Efudex,
,Elacestrant Dihydrochloride,
,Elahere,
,Eligard,
,Elitek,
,Ellence,
,Elotuzumab,
,Eloxatin,
,Elranatamab-bcmm,
,Elrexfio,
,Eltrombopag Olamine,
,Elzonris,
,Emapalumab-lzsg,
,Emend,
,Empliciti,
,Enasidenib Mesylate,
,Encorafenib,
,Enfortumab Vedotin-ejfv,
,Enhertu,
,Ensacove,
,Ensartinib Hydrochloride,
,Entrectinib,
,Enzalutamide,
,Epcoritamab-bysp,
,Epirubicin Hydrochloride,
,Epkinly,
,Epoetin Alfa,
,Epogen,
,Erbitux,
,Erdafitinib,
,Eribulin Mesylate,
,Erivedge,
,Erleada,
,Erlotinib Hydrochloride,
,Erwinaze,
,Ethyol,
,Etopophos,
,Etoposide,
,Etoposide Phosphate,
,Everolimus,
,Evista,
,Evomela,
,Exemestane,
,Fam-Trastuzumab Deruxtecan-nxki,
,Fareston,
,Faslodex,
,Fedratinib Hydrochloride,
,Femara,
,Filgrastim,
,Firmagon,
,Fludarabine Phosphate,
,Fluoroplex,
,Fluorouracil Injection,
,Fluorouracil Topical,
,Flutamide,
,Folotyn,
,Fostamatinib Disodium,
,Fotivda,
,Fruquintinib,
,Fruzaqla,
,Fulphila,
,Fulvestrant,
,Futibatinib,
,Fyarro,
,Gamifant,
,Gardasil,
,Gardasil 9,
,Gavreto,
,Gazyva,
,Gefitinib,
,Gemcitabine Hydrochloride,
,Gemtuzumab Ozogamicin,
,Gemzar,
,Gilotrif,
,Gilteritinib Fumarate,
,Glasdegib Maleate,
,Gleevec,
,Gliadel Wafer,
,Glofitamab-gxbm,
,Glucarpidase,
,Goserelin Acetate,
,Grafapex,
,Granisetron,
,Granisetron Hydrochloride,
,Granix,
,Halaven,
,Hemangeol,
,Hepzato,
,Herceptin,
,Herceptin Hylecta,
,"HPV Bivalent Vaccine, Recombinant",
,"HPV Nonavalent Vaccine, Recombinant",
,"HPV Quadrivalent Vaccine, Recombinant",
,Hycamtin,
,Hydrea,
,Hydroxyurea,
,Hyper-CVAD,
,Ibrance,
,Ibritumomab Tiuxetan,
,Ibrutinib,
,Iclusig,
,Idamycin PFS,
,Idarubicin Hydrochloride,
,Idecabtagene Vicleucel,
,Idelalisib,
,Idhifa,
,Ifex,
,Ifosfamide,
,IL-2,
,Imatinib Mesylate,
,Imbruvica,
,Imdelltra,
,Imetelstat Sodium,
,Imfinzi,
,Imiquimod,
,Imjudo,
,Imkeldi,
,Imlygic,
,Inavolisib,
,Infugem,
,Inlyta,
,Inotuzumab Ozogamicin,
,Inqovi,
,Inrebic,
,"Interferon Alfa-2b, Recombinant",
,Interleukin-2,
,Intron A,
,Iobenguane I 131,
,Ipilimumab,
,Iressa,
,Irinotecan Hydrochloride,
,Irinotecan Sucrosofate,
,Isatuximab-irfc,
,Istodax,
,Itovebi,
,Ivosidenib,
,Iwilfin,
,Ixabepilone,
,Ixazomib Citrate,
,Ixempra,
,Jakafi,
,Jaypirca,
,Jelmyto,
,Jemperli,
,Jevtana,
,Kadcyla,
,Kepivance,
,Keytruda,
,Kimmtrak,
,Kisqali,
,Kisqali Femara Co-Pack,
,Koselugo,
,Krazati,
,Kymriah,
,Kyprolis,
,Lanreotide Acetate,
,Lapatinib Ditosylate,
,Larotrectinib Sulfate,
,Lazcluze,
,Lazertinib Mesylate Hydrate,
,Lenalidomide,
,Lenvatinib Mesylate,
,Lenvima,
,Letrozole,
,Leucovorin Calcium,
,Leukeran,
,Leuprolide Acetate,
,Leuprolide Mesylate,
,Levulan Kerastick,
,Libtayo,
,Lifileucel,
,Lisocabtagene Maraleucel,
,Lomustine,
,Loncastuximab Tesirine-lpyl,
,Lonsurf,
,Loqtorzi,
,Lorbrena,
,Lorlatinib,
,Lu 177-Dotatate,
,Lumakras,
,Lunsumio,
,Lupron Depot,
,Lurbinectedin,
,Luspatercept-aamt,
,Lutathera,
,Lutetium,
,Lutetium Lu 177 Vipivotide Tetraxetan,
,Lutetium Lu 177-Dotatate,
,Lymphir,
,Lynparza,
,Lytgobi,
,Margenza,
,Margetuximab-cmkb,
,Matulane,
,Mechlorethamine Hydrochloride,
,Megestrol Acetate,
,Mekinist,
,Mektovi,
,Melphalan,
,Melphalan Hydrochloride,
,Mercaptopurine,
,Mesna,
,Mesnex,
,Methotrexate Sodium,
,Methotrexate Sodium,
,Methylnaltrexone Bromide,
,Midostaurin,
,Mirvetuximab Soravtansine-gynx,
,Mitomycin,
,Mitoxantrone Hydrochloride,
,Mogamulizumab-kpkc,
,Momelotinib Dihydrochloride Monohydrate,
,Monjuvi,
,Mosunetuzumab-axgb,
,Mozobil,
,Mvasi,
,Myleran,
,Mylotarg,
,Nadofaragene Firadenovec-vncg,
,Nanoparticle Paclitaxel,
,Naxitamab-gqgk,
,Necitumumab,
,Nelarabine,
,Neratinib Maleate,
,Nerlynx,
,Netupitant and Palonosetron Hydrochloride,
,Neulasta,
,Neupogen,
,Nexavar,
,Nilandron,
,Nilotinib,
,Nilutamide,
,Ninlaro,
,Niraparib Tosylate Monohydrate,
,Niraparib Tosylate Monohydrate and Abiraterone Acetate,
,Nirogacestat Hydrobromide,
,Nivestym,
,Nivolumab,
,Nivolumab and Hyaluronidase-nvhy,
,Nivolumab and Relatlimab-rmbw,
,Nogapendekin Alfa Inbakicept-pmln,
,Nplate,
,Nubeqa,
,Nyvepria,
,Obecabtagene Autoleucel,
,Obinutuzumab,
,Odomzo,
,Ofatumumab,
,Ogsiveo,
,Ojemda,
,Ojjaara,
,Olaparib,
,Olutasidenib,
,Omacetaxine Mepesuccinate,
,Oncaspar,
,Ondansetron Hydrochloride,
,Onivyde,
,Onureg,
,Opdivo,
,Opdivo Qvantig,
,Opdualag,
,Orgovyx,
,Orserdu,
,Osimertinib Mesylate,
,Oxaliplatin,
,Paclitaxel,
,Paclitaxel Albumin-stabilized Nanoparticle Formulation,
,Pacritinib Citrate,
,Padcev,
,Palbociclib,
,Palifermin,
,Palonosetron Hydrochloride,
,Palonosetron Hydrochloride and Netupitant,
,Pamidronate Disodium,
,Panitumumab,
,Paraplatin,
,Pazopanib Hydrochloride,
,Pegaspargase,
,Pegfilgrastim,
,Pemazyre,
,Pembrolizumab,
,Pemetrexed Disodium,
,Pemigatinib,
,Penpulimab-kcqx,
,Perjeta,
,Pertuzumab,
,"Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf",
,Pexidartinib Hydrochloride,
,Phesgo,
,Piqray,
,Pirtobrutinib,
,Plerixafor,
,Pluvicto,
,Polatuzumab Vedotin-piiq,
,Polivy,
,Pomalidomide,
,Pomalyst,
,Ponatinib Hydrochloride,
,Portrazza,
,Poteligeo,
,Pralatrexate,
,Pralsetinib,
,Prednisone,
,Procarbazine Hydrochloride,
,Procrit,
,Proleukin,
,Prolia,
,Promacta,
,Propranolol Hydrochloride,
,Provenge,
,Purinethol,
,Purixan,
,Qinlock,
,Quizartinib Dihydrochloride,
,Radium 223 Dichloride,
,Raloxifene Hydrochloride,
,Ramucirumab,
,Rasburicase,
,Ravulizumab-cwvz,
,Reblozyl,
,Recombinant HPV Bivalent Vaccine,
,Recombinant HPV Nonavalent Vaccine,
,Recombinant HPV Quadrivalent Vaccine,
,Recombinant Human Papillomavirus (HPV) Bivalent Vaccine,
,Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine,
,Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine,
,Recombinant Interferon Alfa-2b,
,Regorafenib,
,Relistor,
,Relugolix,
,Repotrectinib,
,Retacrit,
,Retevmo,
,Retifanlimab-dlwr,
,Revlimid,
,Revuforj,
,Revumenib Citrate,
,Rezlidhia,
,Riabni,
,Ribociclib Succinate,
,Ribociclib Succinate and Letrozole,
,Ribociclib Succinate,
,Ripretinib,
,Rituxan,
,Rituxan Hycela,
,Rituximab,
,Rituximab and Hyaluronidase Human,
,Rolapitant Hydrochloride,
,Romidepsin,
,Romiplostim,
,Romvimza,
,Ropeginterferon Alfa-2b-njft,
,Rozlytrek,
,Rubraca,
,Rucaparib Camsylate,
,Ruxience,
,Ruxolitinib Phosphate,
,Rybrevant,
,Rydapt,
,Rylaze,
,Rytelo,
,Sacituzumab Govitecan-hziy,
,Sancuso,
,Sarclisa,
,Scemblix,
,Sclerosol Intrapleural Aerosol,
,Selinexor,
,Selpercatinib,
,Selumetinib Sulfate,
,Siltuximab,
,Sipuleucel-T,
,Sipuleucel T,
,Sirolimus Protein-Bound Particles,
,Soltamox,
,Somatuline Depot,
,Sonidegib,
,Sorafenib Tosylate,
,Sotorasib,
,Sprycel,
,Sterile Talc Powder,
,Steritalc,
,Stivarga,
,Sunitinib Malate,
,Sustol,
,Sutent,
,Sylvant,
,Synribo,
,Tabloid,
,Tabrecta,
,Tafasitamab-cxix,
,Tafinlar,
,Tagraxofusp-erzs,
,Tagrisso,
,Talazoparib Tosylate,
,Talc,
,Talimogene Laherparepvec,
,Talquetamab-tgvs,
,Talvey,
,Talzenna,
,Tamoxifen Citrate,
,Tarceva,
,Targretin,
,Tarlatamab-dlle,
,Tasigna,
,Tavalisse,
,Taxotere,
,Tazemetostat Hydrobromide,
,Tazverik,
,Tebentafusp-tebn,
,Tebentafusp tebn,
,Tecartus,
,Tecelra,
,Tecentriq,
,Tecentriq Hybreza,
,Teclistamab-cqyv,
,Teclistamab cqyv,
,Tecvayli,
,Temodar,
,Temozolomide,
,Temsirolimus,
,Tepadina,
,Tepmetko,
,Tepotinib Hydrochloride,
,Tevimbra,
,Thalidomide,
,Thalomid,
,Thioguanine,
,Thiotepa,
,Tibsovo,
,Tisagenlecleucel,
,Tislelizumab-jsgr,
,Tisotumab Vedotin-tftv,
,Tivdak,
,Tivozanib Hydrochloride,
,Tocilizumab,
,Tolak,
,Topotecan Hydrochloride,
,Toremifene,
,Toripalimab-tpzi,
,Torisel,
,Totect,
,Tovorafenib,
,Trabectedin,
,Trametinib Dimethyl Sulfoxide,
,Trametinib Dimethyl Sulfoxide,
,Trastuzumab,
,Trastuzumab and Hyaluronidase-oysk,
,Treanda,
,Trelstar,
,Trelstar Depot,
,Tremelimumab-actl,
,Treosulfan,
,Trexall,
,Trifluridine and Tipiracil Hydrochloride,
,Triptorelin Pamoate,
,Trisenox,
,Trodelvy,
,Truqap,
,Truxima,
,Tucatinib,
,Tukysa,
,Turalio,
,Tykerb,
,Ultomiris,
,Undencyca,
,Unituxin,
,Unloxcyt,
,Uridine Triacetate,
,Valrubicin,
,Valstar,
,Vandetanib,
,Vanflyta,
,Varubi,
,Vectibix,
,VeIP,
,Velcade,
,Vemurafenib,
,Venclexta,
,Venetoclax,
,Verzenio,
,Vidaza,
,Vimseltinib Dihydrate,
,Vinblastine Sulfate,
,Vincristine Sulfate,
,Vinorelbine Tartrate,
,Vismodegib,
,Vistogard,
,Vitrakvi,
,Vizimpro,
,Vonjo,
,Voranigo,
,Vorasidenib Citrate,
,Voraxaze,
,Vorinostat,
,Votrient,
,Vyloy,
,Vyxeos,
,Welireg,
,Xalkori,
,Xatmep,
,Xeloda,
,Xgeva,
,Xofigo,
,Xospata,
,Xpovio,
,Xtandi,
,Yervoy,
,Yescarta,
,Yondelis,
,Yonsa,
,Zaltrap,
,Zanidatamab-hrii,
,Zanubrutinib,
,Zarxio,
,Zejula,
,Zelboraf,
,Zenocutuzumab-zbco,
,Zepzelca,
,Zevalin,
,Ziextenzo,
,Ziihera,
,Zinecard,
,Zirabev,
,Ziv-Aflibercept,
,Zofran,
,Zoladex,
,Zolbetuximab-clzb,
,Zoledronic Acid,
,Zolinza,
,Zometa,
,Zyclara,
,Zydelig,
,Zykadia,
,Zynlonta,
,Zynyz,
,Zytiga,
,Metastatic Gastroenteropancreatic Neuroendocrine Tumors,
,Neuroendocrine Tumors,
,Metastatic Colorectal Cancer,
,Colorectal Cancer,
,Carcinoma Colorectal,
,Post-Colonoscopy Colorectal Cancer ,
,Colorectal Carcinoma ,
,Colo-rectal Cancer ,
,Colorectal Cancers ,
,Colon Rectal Cancer ,
,Colorectal Carcinomas ,
,Colorectal Neoplasm ,
,MSI-H/dMMR Colorectal Cancer ,
,Adenocarcinoma Renal ,
,Advanced Renal Cell Carcinoma ,
,Clear Cell Renal Cell Carcinoma ,
,Clear-Cell-Renal-Cell Carcinoma ,
,Metastatic Renal Cell Carcinoma ,
,Renal Cell Carcinoma ,
,Renal Cancers ,
,Renal Carcinoma ,
,Renal Cell Adenocarcinoma ,
,Renal Cell Cancer ,
,Renal Cell Carcinomas ,
,Renal Clear Cell Carcinoma ,
,Renal Malignant Tumor ,
,Non-Clear Cell Renal Cell Carcinoma ,
,Zanzalintinib,
,belzutifan,
,Pamiparib,
,TOURMALINE-MM1,
,TOURMALINE MM1,
,CARBOPLATIN-TAXOL,
,CARBOPLATIN TAXOL,
,CHLORAMBUCIL-PREDNISONE,
,CHLORAMBUCIL PREDNISONE,
,FOLFIRI,
,FOLFIRI BEVACIZUMAB,
,FOLFIRI-BEVACIZUMAB,
,FOLFIRI-CETUXIMAB,
,FOLFIRI CETUXIMAB,
,GEMCITABINE-CISPLATIN,
,GEMCITABINE CISPLATIN,
,GEMCITABINE-OXALIPLATIN,
,GEMCITABINE OXALIPLATIN,
